← Eichor
Condition: Multiple Myeloma Refractory To Standard Treatment Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Multiple Myeloma Refractory To Standard Treatment

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Part
Phase 1 · 42 location(s) · Regeneron Pharmaceuticals · NCT05137054A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or
Phase 3 · 141 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT06615479A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care C
Phase 3 · 20 location(s) · Regeneron Pharmaceuticals · NCT07222761Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
Phase 2 · 1 location(s) · Polina Stepensky · NCT06971380
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.